The invention provides an application of a
Galectin-3 inhibitor TD139 in the treatment of tuberculous
granuloma. The TD 139 is proved to be a specific inhibitor of the
Galectin-3, and the TD 139 is a specific inhibitor of the
Galectin-3. According to the invention, the dosage of
intraperitoneal injection of mice is 200 [mu] g / mouse. D <-1 >. By adopting the technical scheme of the invention to treat a
mycobacterium marinum induced mouse
tuberculosis model through the TD139, the formation of tuberculous
granuloma is reduced
in vivo through the TD139. TD139 is subjected to
intraperitoneal injection once
every other day and 5 times continuously, the
granuloma area, the
intracellular bacterium carrying amount and the inflammatory factor expression of the
tail skin of a
tuberculosis model can be remarkably reduced, and mice do not die in the whole process; the intrinsic mechanism is that PDIM is a toxic structure of a
mycobacterium marinum bacterial wall and causes
skin ulceration and granuloma. The Galectin-3
gene can inhibit
phagocytosis and
elimination of
Mycobacterium marinum by macrophages and activation of innate immune pathways of the
Mycobacterium marinum, and TD139 promotes the macrophages to eliminate
pathogenic bacteria and reduces MMP-9 expression, so that formation of granuloma is reduced. The new pharmacological
efficacy and the
tuberculosis treatment mechanism of the TD139 are found for the first time, and a foundation is laid for future clinical application.